Clinical Decision Support Tool for Infliximab in Crohn’s Disease

Biologic treatment options for Crohn's disease (CD) are increasing and providers will need enhanced support in integrating these therapies into routine practice. Using phase 3 clinical trial programs in CD, we have previously built and validated clinical decision support tools for achieving clinical remission (CREM) with vedolizumab and ustekinumab in CD.^1-4 We now aim to develop a clinical decision support tool for infliximab in CD.